• Product NameItacitinib
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityItacitinib (INCB039110) is an oral selective JAK1 inhibitor.Itacitinib potently inhibits OCT2-mediated uptake of creatinine as well as MATE1-/MATE2-K-mediated efflux of creatinine. Itacitinib causes a dose-dependent decrease in transcellular transport of creatinine with weaker net inhibition compared with the effects on individual transporters.
• Target NameJAK inhibitor
• CAS No. 1334298-90-6
• Calculated MW 553.53
• Formulation C26H23F4N9O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Immunology
  SMILES:C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F
  Pathways:Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells
  Receptor:JAK1
  Boling pt:
  Melting pt:
  Solubility:DMSO: 30 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Bissonnette R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatolog Treat. 2016 Aug;27(4):332-8.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting